Weight Loss Drugs In India
- All
- News
-
Weight-Loss Drug Misuse Under Scanner, Centre Warns Of Legal Action For Violations
The crackdown comes at a time when GLP-1 drugs, widely used for weight loss and diabetes, are seeing a surge in demand, but are increasingly being accessed without proper prescriptions through retail and digital channels.
-
Semaglutide Weight-Loss Drugs May Help Prevent Deadly Heart Attack Complications
Popular weight-loss drugs like semaglutide may reduce life-threatening complications after heart attacks, a UK study finds. By improving blood flow in tiny vessels, these drugs could help the heart recover, but human trials are still needed.
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
How A YouTuber Lost 10 Kg With Mounjaro And What It Did To His Emotions: 'Life Was Flat'
A YouTuber shared that while he lost 10 kg with Mounjaro, he also felt deprived of emotions. Irrespective of the situation, he remained neutral
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
Weight-Loss Drug Misuse Under Scanner, Centre Warns Of Legal Action For Violations
The crackdown comes at a time when GLP-1 drugs, widely used for weight loss and diabetes, are seeing a surge in demand, but are increasingly being accessed without proper prescriptions through retail and digital channels.
-
Semaglutide Weight-Loss Drugs May Help Prevent Deadly Heart Attack Complications
Popular weight-loss drugs like semaglutide may reduce life-threatening complications after heart attacks, a UK study finds. By improving blood flow in tiny vessels, these drugs could help the heart recover, but human trials are still needed.
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
How A YouTuber Lost 10 Kg With Mounjaro And What It Did To His Emotions: 'Life Was Flat'
A YouTuber shared that while he lost 10 kg with Mounjaro, he also felt deprived of emotions. Irrespective of the situation, he remained neutral
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
